These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1143 related items for PubMed ID: 19863849

  • 21. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.
    Lilyasari O, Subekti Y, Atika N, Dinarti LK, Putri S, Opitasari C, Anggraini AB, Bussabawalai T, Teerawattananon Y.
    BMC Health Serv Res; 2019 Aug 14; 19(1):573. PubMed ID: 31412857
    [Abstract] [Full Text] [Related]

  • 22. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 Aug 14; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 23. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M, Galiè N.
    J Am Coll Cardiol; 2009 Mar 03; 53(9):733-40. PubMed ID: 19245962
    [Abstract] [Full Text] [Related]

  • 24. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
    Raposo-Sonnenfeld I, Otero-González I, Blanco-Aparicio M, Ferrer-Barba A, Medrano-López C.
    Rev Esp Cardiol; 2007 Apr 03; 60(4):366-72. PubMed ID: 17521545
    [Abstract] [Full Text] [Related]

  • 25. Role of iloprost and bosentan in pulmonary arterial hypertension.
    Saleh JA.
    Niger J Med; 2008 Apr 03; 17(1):13-9. PubMed ID: 18390125
    [Abstract] [Full Text] [Related]

  • 26. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
    Wang S, Yu M, Zheng X, Dong S.
    Drug Deliv; 2018 Nov 03; 25(1):1898-1909. PubMed ID: 30442035
    [Abstract] [Full Text] [Related]

  • 27. Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.
    Strange G, Keogh A, Dalton B, Gabbay E.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun 03; 11(3):253-63. PubMed ID: 21671693
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
    Don GW, Joseph F, Celermajer DS, Corte TJ.
    Intern Med J; 2012 Dec 03; 42(12):1351-4. PubMed ID: 23253000
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
    Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F.
    Ann Intern Med; 2002 Apr 02; 136(7):515-22. PubMed ID: 11926786
    [Abstract] [Full Text] [Related]

  • 34. Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
    Highland KB, Strange C, Mazur J, Simpson KN.
    Chest; 2003 Dec 02; 124(6):2087-92. PubMed ID: 14665484
    [Abstract] [Full Text] [Related]

  • 35. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G, Toscano A, Bevilacqua M, Di Chiara L, Parisi F.
    Pediatr Transplant; 2007 Feb 02; 11(1):110-2. PubMed ID: 17239133
    [Abstract] [Full Text] [Related]

  • 36. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 37. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
    Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG.
    Rheumatology (Oxford); 2010 Nov 04; 49(11):2147-53. PubMed ID: 20675359
    [Abstract] [Full Text] [Related]

  • 38. Bosentan for the treatment of portopulmonary hypertension.
    Tempe DK, Datt V, Datta D.
    Ann Card Anaesth; 2008 Nov 04; 11(2):139-40; author reply 140. PubMed ID: 18603763
    [No Abstract] [Full Text] [Related]

  • 39. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
    Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F.
    J Am Coll Cardiol; 2003 Jul 02; 42(1):158-64. PubMed ID: 12849677
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.